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Abstract:  Sickle cell disease (SCD) is a pleiotropic genetic disorder of 
hemoglobin that has profound multi-organ effects.  The low prevalence of SCD 
(∼100,000/US) has limited progress in clinical, basic, and translational research.  
Lack of a large, readily accessible population for clinical studies has contributed 
to the absence of standard definitions and diagnostic criteria for the numerous 
complications of SCD and inadequate understanding of SCD pathophysiology.  
In 2005, the Comprehensive Sickle Cell Centers initiated a project to establish 
consensus definitions of the most frequently occurring complications.  A group of 
clinicians and scientists with extensive expertise in research and treatment of 
SCD gathered to identify and categorize the most common complications.  From 
this group, a formal writing team was formed that further reviewed the literature, 
sought specialist input, and produced definitions in a standard format.  This 
manuscript provides an overview of the process and describes twelve body 
system categories and the most prevalent or severe complications within these 
categories.  A detailed Appendix provides standardized definitions for all 
complications identified within each system.  This report proposes use of these 
definitions for studies of SCD complications, so future studies can be comparably 
robust and treatment efficacy measured.  Use of these definitions will support 
greater accuracy in genotype-phenotype studies, thereby achieving a better 
understanding of SCD pathophysiology.  This should nevertheless be viewed as 
a dynamic rather than final document; phenotype descriptions should be 
reevaluated and revised periodically to provide the most current standard 
definitions as etiologic factors are better understood and new diagnostic options 
are developed. 
Introduction 
Sickle cell disease (SCD) is an inherited disorder due to homozygosity for the 
sickle β-globin gene mutation at position 6 (glu → val), or double heterozygosity 
for the sickle gene and another mutation for a different hemoglobin variant or one 
of numerous β-thalassemia mutations.  SCD is a systemic pleiotropic disease 
that affects nearly all organs during the life of afflicted patients.  Specific 
phenotypic manifestations of the disease are protean in nature and vary 
considerably in frequency and severity latitudinally among patients and 
longitudinally in the same patient over time. 
The lack of universally accepted nomenclature and diagnostic criteria for the 
complications of SCD has been confusing to patients, their families, the public, 
and providers, and has hampered clinical research efforts to collect outcome 
data and compare research methods and findings.  This report defines selected 
complications of SCD in a uniform manner, drawing on recently published 
literature and the expertise of a broad variety of active clinicians and 
investigators.  The goals are to provide current consensus definitions of the 
phenotypic manifestations of SCD and to facilitate research by establishing a 
common basis for comparison of data. 
Therefore, this paper describes the complications that are particularly 
characteristic of SCD and are due to the sequence of events that result from the 
pathophysiologic biology of the abnormal sickle red cell.  These complications 
are placed within one of twelve broad categories classified according to basic 
system/organ involvement and are represented by bold headings.  Ten specific 
complications have been selected for discussion in detail due to their relative 
frequency and/or potential severity, and are indicated by underlined subheadings 
within the appropriate category sections.  In addition, controversies regarding 
these complications are discussed.  The formal definitions for these 
complications are included in an accompanying Appendix. 
The Appendix, available online at this journal’s website, includes all 62 selected 
complications listed within their respective categories, including those unique to 
SCD and those that are secondary in nature or due to co-morbidities.  The 
Appendix includes the following for each complication:  Definition, Diagnostic 
Criteria, Severity Index, Classification, and References.  The purpose of the 
Appendix is to provide practitioners and investigators with a concise reference 
describing the major features of each complication and its associated diagnostic 
tests and, where applicable, measures of severity. 
The description of each complication is evidence-based whenever possible.  For 
some complications, no published evidence or standard was found for the 
Severity Index and/or the Classification.  In some situations, the authors have 
recommended descriptions based on the vast experience of experts in SCD and 
have noted the descriptions as such. 
Methods 
Background 
The Statistics and Data Management Center (SDMC) of the National Heart, 
Lung, and Blood Institute (NHLBI) Comprehensive Sickle Cell Centers (CSCC) 
Program was charged in 2003 with establishing a database of clinical, quality of 
life, and outcomes data to support development of multi-center research on SCD.  
A committee composed of representatives from 5 of the 10 participating clinical 
centers (C-Data Protocol Committee) assisted the SDMC in developing a 
protocol for this Collaborative Data Project (C-Data).  The SDMC and C-Data 
Protocol Committee created a detailed case report form (CRF) designed to 
obtain comprehensive clinical, surgical, hospitalization, and laboratory data from 
medical record review to focus data collection on those features considered most 
important and most useful in identifying potential subjects for future trials.  
However, the lack of standard, universally applied definitions for clinical 
conditions or phenotypes used in the context of SCD initially threatened to make 
the collection of uniform data from existing medical records across sites 
impractical and likely impossible.  Therefore, the Committee recommended 
initiation of a formal effort to establish standardized definitions for use in C-Data 
prospective data collection, CSCC future studies, and SCD research in general. 
In parallel with this effort, an NIH-sponsored conference, “New Directions for 
Sickle Cell Therapy in the Genome Era”, listed as its highest priority the 
establishment of a SCD network that would include a comprehensive patient 
database and a biological sample repository to support examination of 
phenotypic diversity and serve as a resource for future research.  As a result, the 
CSCC Center Directors, with support from the NHLBI, endorsed expansion of the 
C-Data Project to include the collection, testing, and storage of blood and DNA 
samples from participants.  Based on this decision and the earlier 
recommendation of the C-Data Protocol Committee, the CSCC Steering 
Committee approved formation of an ad hoc work group to establish consensus 
definitions of the phenotypic manifestations of SCD.   
Preliminary and Work Group Activities 
The work group was composed of 16 clinicians and scientists with extensive 
expertise in research and treatment of SCD, representing the ten clinical centers 
and the SDMC, and chaired by Dr. Marilyn Telen of Duke University Medical 
Center.  Dr. Lieff and the SDMC staff established several tools prior to the 
meeting to facilitate the group’s work.  A list of complications, based on literature 
on SCD and complications already included in the C-Data medical history CRF, 
was compiled by the SDMC and further refined by the C-Data Protocol 
Committee and the CSCC Program Medical Monitor.  A draft format or schema 
was developed to provide a standardized approach to writing the definitions.  
Group members were assigned to one of six subgroups based on their expertise.  
Each subgroup was given a small set of complications and asked to prepare 
preliminary draft definitions for their complications set, with the goal of having 
good familiarity with the most recent literature and the real variation in 
interpretation and application of a diagnosis for a given complication.  Work 
group members received this information 2 weeks in advance and were asked to 
provide feedback prior to the meeting.   
The 2-day meeting began with a large group discussion of the history, rationale, 
and goals of the CSCC’s priority effort to develop standardized phenotype 
definitions.  Subgroups then received the set of draft definitions for their assigned 
complications, which had been revised based on member responses submitted 
previously.  The subgroups met separately to rewrite or refine the definitions.  
Groups were asked to include what most experts accept as a definition of the 
complication in question, as well as the supporting diagnostic criteria or 
measurements needed to confirm the diagnosis.  If appropriate, levels of 
certainty for the diagnosis were to be indicated; an MRI for example, may be 
considered the “gold standard” for determination of a cerebrovascular accident 
(CVA), whereas a neurological exam is viewed with less certainty. 
The large group reconvened to review the subsequent drafts and provide 
feedback.  This process was repeated a second time.  At the final group session, 
some definitions were excluded and a few added, remaining questions for 
specific complications identified, and plans made to finalize the set of definitions 
for submission to the Steering Committee for approval.   
The C-Data Protocol Committee met to compare the work group’s approved draft 
definitions to the list of complications captured in C-Data at that time, and revised 
the definitions further.  This group modified the CRFs designed to collect 
prospective clinical data, to accommodate the revised phenotype definitions.  
The final CRFs were approved in June 2006.  Final revisions of definitions 
continued; they were approved by the Steering Committee in July 2007. 
A group of CSCC investigators committed to establishing a final, workable set of 
phenotype definitions for use within the CSCC program and in the SCD research 
community formed a writing group to develop a publishable document that would 
be available to the widest audience possible.  This group, led by Dr. Samir Ballas 
of Thomas Jefferson University, determined the goals and structure of the 
manuscript, and identified the most appropriate site for publication.  The authors 
decided the best approach was to provide an overview of the process, a 
description of the 12 body system categories, a description of the most relevant 
or severe complications within these categories, and to provide the standardized 
definitions for all complications in an Appendix.  A manuscript proposal was 
submitted to and approved by the CSCC Publications Committee.  Professional 
medical writers and editors were involved in the writing and editing process to 
ensure the presence of a logical, standard, and consistent style readily 
accessible and understood by the broad target audience.  The writing group 
worked consistently during the year and a half preceding manuscript submission 
to successfully accomplish these goals, which offer a potentially important 
contribution to SCD research.
Complications of Sickle Cell Disease 
Major clinical manifestations of SCD include three sets of signs and symptoms:  
1) hemolytic anemia and its sequelae as shown in Table 1; 2) pain syndromes 
and related issues as shown in Table 2; 3) complications affecting major organs 
and their sequelae as shown in Table 3.  Definitions of these complications are 
described below and/or in the Appendix.  Co-morbid conditions associated with 
SCD will not be defined in this paper, though some of the relatively common co-
morbid conditions are defined in the Appendix. 
 
Acute Exacerbations of Anemia 
Sickle cell disorders are associated with variable degrees of anemia depending 
on genotype, with the most severe decrease in hemoglobin level seen in sickle 
cell anemia (homozygous hemoglobin S) and the least severe decrease in 
hemoglobin S-β+ thalassemia.  After the first five years of life, the hemoglobin 
concentration in an individual patient usually remains constant in the steady state 
over time.  However, clinically significant acute lowering of the hemoglobin 
concentration below steady state values does occur episodically.  These 
episodes may result from a variety of causes, including hyperhemolysis, acute 
splenic sequestration, and aplastic crises.  Characteristics of these episodes are 
described in the Appendix and briefly discussed below.  It is important to 
understand the use of diagnostic tests in the differentiation of these causes of 
exacerbation of anemia, since appropriate treatment is different for each of them.  
Hyperhemolysis 
Although chronic hemolytic anemia is a major feature of sickle cell disorders, a 
marked drop in hemoglobin with evidence of an increased hemolytic rate is 
referred to as hyperhemolysis.  Hyperhemolysis is ordinarily diagnosed when the 
exacerbation of anemia occurs in the absence of other identifiable causes of red 
cell destruction (eg, splenic or hepatic sequestration).  It is most often, but not 
always, accompanied by evidence of increased red blood cell production 
(increased reticulocytosis).  Several sub-phenotypes of hyperhemolysis arising 
from different pathophysiologic mechanisms may complicate the clinical course 
of sickle cell disorders.  One type is related to acute or delayed hemolytic 
transfusion reactions, in which hemolysis may occur due to the “innocent 
bystander mechanism.”i  In the innocent bystander mechanism, both autologous 
and homologous red cells (RBCs) are destroyed.  It is typically, although not 
uniformly, associated with a paradoxical decrease in reticulocyte count.  In 
hemolytic transfusion reactions, homologous (transfused) RBCs are destroyed, 
presumably due to interaction with alloantibodies.  A positive direct antiglobulin 
(or Coombs) test is usually but not uniformly present.  Recognition of the 
hyperhemolysis syndrome is especially important, as hemoglobin levels often 
decrease further with transfusion, even when crossmatch-compatible blood is 
provided.i 
Another type of hyperhemolysis in SCD is not related to blood transfusion but is 
an independent complication of the disease itself, in which autologous RBCs are 
destroyed at an increased rate in the presence or absence of an acute painful 
crisis.  Isolated episodes of hyperhemolysis in the absence of painful crises are 
often referred to as hemolytic crises.ii  Hyperhemolysis may also be drug 
induced. 
It should be noted that a diagnosis of hyperhemolysis in the post-transfusion 
setting can be made only by calculation of the destruction of transfused and 
autologous red blood cells using results of serial blood counts, reticulocyte 
counts, and hemoglobin electrophoresis. 
Acute Splenic Sequestration 
Acute splenic sequestration was first recognized in 1945iii and is one of the leading 
causes of death in children with sickle cell anemia.iv,v,vi  In patients homozygous for 
hemoglobin S, the lifetime prevalence of acute splenic sequestration has been 
reported to be between 7% and 30%.vii,viii  It can occur as early as 8 weeks of ageix, 
though more typically an initial event occurs in the toddler age group.  Patients with 
hemoglobin SC or hemoglobin S/β-thalassemia tend to have a first event later in 
life, even into adulthood.x,xi  Although acute splenic sequestration is often 
associated with an infectious trigger, it may also be unprovoked.viii,xii 
Acute splenic sequestration is characterized by a tender, rapidly enlarging, and 
sometimes massive spleen due to the trapping of sickle erythrocytes and other 
blood constitutents and may lead to shock due to loss of effective circulating 
volume.  The hemoglobin concentration decreases from baseline by at least 2 g/dL, 
usually with evidence of reticulocytosis and often moderate to severe 
thrombocytopenia.  Prompt recognition of acute splenic sequestration is critical to 
the provision of appropriate and timely therapy of this life-threatening complication. 
Aplastic Crises 
Since SCD patients rely on constant overproduction of RBCs to maintain even 
their baseline low hemoglobin levels, any process that interferes with 
erythropoiesis can result quickly in severe anemia.  Erythropoiesis can be 
suppressed by almost any infectious or inflammatory process to some degree, 
but occasionally severe transient red cell aplasia (absolute reticulocyte count 
<50,000/ul) occurs, leading swiftly to severe anemia.  Among infectious causes, 
parvovirus B19 infection classically causes the most severe reticulocytopenia, 
often to levels <20,000/ul.xiii 
 
Cardiac Complications 
Sickle cell disorders are associated with multiple clinically significant cardiac 
abnormalities, primarily but not exclusively in adults.  The anemia of SCD is 
associated with a chronic high cardiac output state, the physiological sequelae of 
which are not completely understood.  Morphologic and physiologic changes 
include a thickened interventricular septum, increased left ventricular mass, 
abnormal left ventricular diastolic filling, and left ventricular diastolic dysfunction, 
among others.  Electrocardiograms often provide signs of left ventricular 
hypertrophy and demonstrate nondiagnostic ST and T wave abnormalities, as 
well as conduction abnormalities.  Increased preload and decreased afterload 
help maintain a normal or high ejection fraction despite these abnormalities, 
unless and until decompensation occurs.  The impact of these cardiac findings is 
not clearly delineated, but they have been proposed to affect oxygen transport 
and delivery and may also contribute to the relatively high incidence of sudden 
death among SCD patients.  Cardiac dysfunction also potentially has implications 
for other end-organ functions. 
 
Disturbances of Growth and Development 
Children with sickle cell disorders have significantly decreased height, weight, 
and body mass index (BMI), as well as delayed sexual maturation, when 
compared with control subjects.xiv  Inadequate nutrition, abnormal endocrine 
function, and, in particular, increased caloric requirements due to elevated 
energy expenditure may all be etiologic factors.  Although definitive evidence is 
lacking, growth may be enhanced by chronic transfusion, increased caloric 
intake, or hydroxyurea.  In order to evaluate the effects of interventions on growth 
in persons with sickle cell disorders, comparison with standardized growth charts, 
such as those from the US National Center for Health Statistics (NCHS), may be 
utilized, with growth expressed as Z-scores (the number of standard deviations 
below or above the “normal” mean for age). 
 
Gastrointestinal/Hepatobiliary Complications 
Hepatobiliary pathology in sickle cell disorders is common but not always related 
specifically to the underlying SCD.  For example, the definitions presented in the 
Appendix for cholecystitis, cholelithiasis, pancreatitis, and viral hepatitis are not 
unique to sickle cell disorders, although their incidence may be more common in 
this group than in the general population.  Hepatic sequestration and intrahepatic 
cholestasis, however, are virtually unique to sickle cell disorders, and their 
definitions are of specific interest to hematologists. 
Acute Hepatic Sequestration / Intrahepatic Cholestasis 
Sequestration of red cells and other blood cells may also take place in the liver, 
either in isolation or in combination with splenic sequestration.  Tender, progressive 
hepatomegaly, accentuated anemia below baseline, reticulocytosis, and 
hyperbilirubinemia are the usual clinical features of hepatic sequestration and can 
mimic acute cholecystitis or viral hepatitis, although sequestration usually is 
accompanied by less pronounced transaminitis and lack of elevation of pancreatic 
enzymes.xv,xvi,xvii  Hepatic sequestration is not usually life-threatening, because the 
liver is not as distensible as the spleen and therefore pooling of red blood cells is 
rarely significant enough to cause cardiovascular collapse.  However, it can lead to 
decreased liver function and, like splenic sequestration, usually responds to 
transfusion.  Intrahepatic cholestasis (ie, obstruction of bile formation or flow) can 
occur in the setting of hepatic sequestration, leading not only to 
hyperbilirubinemia but also to striking hepatic dysfunction, with marked 
deterioration of synthetic function.  Blood exchange transfusion is often needed 
for intrahepatic cholestasis. 
 
Muscular/Skeletal/Skin Complications 
Dactylitis, avascular necrosis, leg ulcers, osteomyelitis, osteopenia, and 
osteoporosis are frequent in patients with sickle cell disorders.  The clinical 
features are similar to those in individuals without SCD, but the age at 
presentation is earlier and the response to interventions, when required, is poor.  
Musculoskeletal and dermatologic complications are often due to vaso-occlusion, 
but hemolysis, infection, and chronic co-morbidities can have detrimental 
consequences if not addressed.  Swelling, erythema, and fever can occur from 
cell death due to hemolysis.  Patients with dactylitis, bone infarction, or leg ulcers 
develop pain at the involved site, but swelling, erythema, and fever may occur, 
implying the possibility of infection as an underlying or complicating feature.  
When recurrent leg ulcers and myositis develop, co-morbidities such as diabetes 
and rheumatologic conditions such as systemic lupus erythematosus should be 
considered.  
 
Neurologic Complications 
The effects of sickle cell disorders on the brain vary with age, may be acute or 
chronic, may be clinically overt or subtle (“silent”), and may result in significant 
morbidity and even mortality.  The underlying cerebrovascular lesions also vary 
from extensive, large vessel distribution infarcts to the “silent” infarcts associated 
with microvascular disease.  Central nervous system lesions may be infarctive 
due to vaso-occlusion, hemorrhage, or both. 
Cerebrovascular Accident 
Cerebrovascular accident (CVA) was previously defined by the CSSCD as an 
acute neurological syndrome secondary to occlusion of an artery or hemorrhage, 
with resultant ischemia and neurologic signs and symptoms.  A small fraction of 
the strokes in children, but the majority of those in adults, are hemorrhagic, with 
intraventricular, intracerebral, or subarachnoid bleeding.  Like the previous 
Cooperative Study of Sickle Cell Disease (CSSCD) definitions for 
cerebrovascular complications, the symptomatic manifestations of stroke rely on 
physical exam findings but have been modified to include evidence-based 
practice and imaging techniques to objectively confirm brain lesions and vascular 
pathology.  The availability of diffusion-weighted intensity (DWI) MRI has 
facilitated the early detection of acute ischemia and provides an objective 
measure by which to define and classify stroke subtypes.  Noninvasive imaging 
by MRA is now routinely used to document stenosis or obstruction of flow in the 
large intracranial vessels, as well as abnormal vessel formation, including 
moyamoya, and correlates well with standard angiography. 
The use of transcranial Doppler (TCD) ultrasonography to identify sickle cell 
patients at increased risk for stroke was introduced in the early 1990s, validated 
in a series of studies, and demonstrated in the STOP trial (a phase III 
randomized, prospective, multicenter clinical trial of chronic transfusion versus 
standard observation) to be remarkably useful in identifying patients at risk for 
this devastating complication.xviii  We have adopted the definitions for normal, 
conditional (borderline), and abnormal TCD velocities used in the STOP studies:  
time-averaged mean of the maximum velocity in the middle cerebral or distal 
carotid artery <170, 170-199, and ≥200 cm/sec, respectively.  An important part 
of the definition is that TCD studies should be performed in patients under 
steady-state conditions by an experienced technologist. 
Transient Ischemic Attacks 
Transient ischemic attacks (TIAs) are relatively infrequent events in persons with 
sickle cell disorders, but their occurrence indicates an increased risk for overt 
stroke.  Until recently, TIA was defined by neurologic dysfunction caused by focal 
brain ischemia with symptoms lasting up to 24 hours, but recent neurology 
literature has utilized a period of symptomatology that is typically less than 1 
hour.xix  Resolution of neurologic symptoms and a lack of lesions in the region 
corresponding to symptoms on neuroimaging are also elements in the current 
definition of TIA. 
Silent Cerebral Infarcts 
Silent cerebral infarcts were initially described in the CSSCD based on brain MRI 
findings in children with normal neurologic examinations.xx  Subclinical infarcts 
detected by MRI are actually not “silent,” since we now know that they are 
associated with neurocognitive deficits (and an increased risk for overt stroke).  
An important part of this definition is that these lesions cannot be attributed to an 
overt neurologic event or finding. 
 
Ophthalmologic Complications 
Ophthalmologic complications of sickle cell disorders are relatively common and 
may occur in any vascular bed of the eye.  Sickle cell eye disease may be 
insidious in nature and may not be detected at its early stages unless an eye 
exam is performed annually.  Annual eye examinations in this population should 
include an accurate measurement of visual acuity and intraocular pressure, 
examination of the anterior structures of the eye using a slit lamp biomicroscope, 
and examination of the posterior structures of the eye, including the retina, 
through dilated pupils and using fluorescein angiography.  In general, diagnostic 
criteria for SCD patients are the same as for causes of ocular pathology in other 
populations. 
 
Pain Syndromes 
Sickle cell pain is unique in that it occurs as a hallmark feature in a genetic 
disorder as early as infancy and throughout a lifetime.  SCD-associated pain can 
be acute, subacute, chronic, or episodic.  Patients may experience somatic, 
visceral, neuropathic, or even iatrogenic pain.  While pain is most often 
spontaneous, it is occasionally evoked, but rarely psychogenic.  Sickle cell pain 
syndromes vary in character and intensity depending on the location and severity 
of tissue damage.  Symptom intensity and duration are influenced by a variety of 
biochemical, neurological, psychosocial, cultural, spiritual, and environmental 
factors that may be further modified by disease or treatment-related effects.  No 
diagnostic tests are currently available to define the extent, location, or severity 
of tissue damage from vaso-occlusion.  Categorization of pain syndromes thus 
relies on careful clinical histories and examinations, as well as the clinical context 
of the pain symptoms.  The pain syndromes described reflect the result of the 
primary disease process and resultant tissue damage (acute sickle cell pain, 
multi-organ system failure), pain characteristics related to nerve damage or 
neuronal dysfunction (neuropathic pain), or consequences of treatment 
(iatrogenic pain syndromes). 
Vaso-occlusive Episodes 
Pain from tissue ischemia as a result of vaso-occlusion is the most common 
complication of SCD.xxi,xxii,xxiii,xxiv,xxv  Vaso-occlusion may occur in a variety of 
vascular beds, but those in the deep muscle, periosteum, and bone marrow 
appear to be most often affected.xxv  These same tissues are also richly 
innervated by nocioceptors activated by a variety of inflammatory mediators.xxi,xxvi  
Recurrent episodes of acute pain (painful crises) lasting for hours to days (or 
rarely weeks), begin early in childhood and often become more frequent in 
adolescents and adults, who additionally may display variable degrees of 
persistent pain related to chronic bone and joint damage.xxi,xxii,xxiii,xxvii,xxviii  
Neurological changes in response to persistent pain can lead to an enhanced 
sensitivity to pain, and psychosocial sequelae can increase subsequent 
suffering.xxi,xxii,xxiii,xxvi 
As pain symptoms are in part a reflection of disease activity, a better 
understanding of disease pathogenesis is an important aspect of sickle pain 
management.  Thus the acute painful episode (painful crisis) evolves through 
four phases:  prodromal, initial, established, and resolving.xxix  Objective 
laboratory signs do occur during these phases in most patients, provided they 
are done serially and compared to established steady-state values.  Moreover, 
recent studies have suggested a vaso-occlusive “phenotype” consisting of 
patients with relatively higher hemoglobin levels who clinically display increased 
frequency of pain, acute chest syndrome, and avascular necrosis.xxx 
 
Pulmonary Complications 
Individuals with sickle cell disorders have a unique pathophysiology that puts the 
microvasculature of the lung at particular risk for complications.  Acute chest 
syndrome is unique to sickle cell syndromes, and physicians must be aware of 
the potential for rapid progression that may prove fatal in the child or adult with 
sickle cell disorders.  Pulmonary hypertension is very common in persons with 
sickle cell disorders and is probably related at least in part to chronic hemolysis 
and nitric oxide consumption, as it occurs in other hemolytic anemias as well.  
The diagnostic criteria required to define pulmonary hypertension are distinct for 
sickle cell disorders.  However, chronic obstructive and restrictive pulmonary 
disease, asthma, obstructive sleep apnea, and pulmonary embolism are not 
unique to patients with sickle cell disorders and are defined as in unaffected 
individuals.  The hypoxia caused by these conditions affects hemoglobin S 
polymerization as well as other aspects of sickle red cell biology and may 
therefore accelerate the microvascular complications of SCD.  This 
pathophysiology requires the caregiver to be cognizant of these potentially 
deleterious consequences.  Recognition of pulmonary embolism is particularly 
difficult in SCD patients.  The recurrent chest or rib pain that is often reported in 
sickle cell disorders may make recognition and diagnosis of non-sickle 
pulmonary conditions such as pulmonary embolism difficult.  The paragraphs 
below list features that may be helpful to diagnose these conditions. 
Acute Chest Syndrome 
The term acute chest syndrome (ACS) reflects the difficulty in distinguishing 
pulmonary infection (viral or bacterial pneumonia) from other conditions that may 
occur in SCD, including inflammatory changes following pulmonary fat embolism 
or pulmonary infarction by microvascular occlusion or thromboembolism.  
Bacterial infection is diagnosed by culture of a respiratory pathogen from sputum 
or blood, but such cultures are negative in the majority of ACS cases.  The 
diagnosis of fat embolism can be established by bronchoalveolar lavage (BAL) 
with examination for lipid-laden macrophages, but while BAL has a higher 
bacterial culture yield,xxxi it is clinically impractical in most instances.  Finally, 
distinguishing thromboemboli from microvascular occlusion using chest 
tomography or lung scintigraphy is difficult, as the findings are nearly 
identical.xxxii,xxxiii  Consequently, the historical term ACS cannot be discarded until 
better diagnostic testing becomes available. 
Acute chest syndrome clinically and radiologically resembles bacterial 
pneumonia.  However, the clinical course of ACS in persons with sickle 
hemoglobinopathies is considerably different from that of pneumonia in 
hematologically normal individuals.  Multiple lobe involvement and recurrent 
infiltrates are more common in SCD, and the duration of clinical illness and of 
radiologic clearing of infiltrates may be prolonged to 10 days or longer.xxxiv,xxxv  
Acute pulmonary infiltrates are particularly difficult to classify in sickle cell 
disorders because of the potential for rapid progression from mild hypoxia to 
pulmonary failure, acute respiratory distress syndrome (ARDS), and multiorgan 
failure as a consequence of disseminated microvascular occlusion.  Any decline 
in arterial oxygen saturation increases the fraction of polymerized Hb S with a 
subsequent deleterious effect on blood flow and pulmonary function. 
ACS is associated with considerable morbidity and both acute and delayed 
mortality.  The incidence is highest in children 2 to 4 years of age and, while 
gradually declining with age, remains common in adults. 
Pulmonary Hypertension 
Pulmonary hypertension (pHTN) has been recognized as an increasingly 
common and deadly complication of sickle cell disorders,xxxvi,xxxvii,xxxviii as well as 
other hemolytic anemias.xxxix  Approximately 40% of adults with SCD can be 
identified as having pHTN; similar proportions are seen in pediatric and 
adolescent patient populations.  In contrast to primary pHTN, however, pHTN in 
SCD tends to exhibit lower pulmonary artery pressures but nevertheless is 
associated with increased mortality.  Adult SCD patients with pHTN have a 6- to 
10-fold higher risk of mortality than do SCD patients without pHTN; however, the 
risk in the pediatric age group is less well defined.  In most studies, pHTN in SCD 
has been defined by the presence of a tricuspid regurgitant jet velocity (TRjet) of 
≥2.5 m/s.  Although this criterion has correlated with markedly reduced survival in 
a number of studies, this diagnostic threshold, though arbitrary, is commonly 
used and corresponds to a pulmonary arterial (PA) systolic pressure of 
approximately 30 mmHg.  When right heart catheterization is done, pulmonary 
artery hypertension is considered present when the mean PA pressure is ≥25 
mmHg.  In addition, many investigators now feel that SCD patients with pHTN 
belong to a subset of patients with a “high hemolytic rate” phenotype.xl  In 
addition to having lower hemoglobin and higher lactate dehydrogenase (LDH) 
levels at baseline,xxxvi,xli patients with pHTN are now also recognized to have 
other sequelae of SCD at higher rates than patients without pHTN.  Patients with 
pHTN exhibit a higher prevalence of proteinuria and decreased glomerular 
filtration rate (GFR),xxxviii as well as left ventricular (usually diastolic) dysfunction, 
leg ulcers, and CNS events.xli  Finally, we do not fully understand the mechanism 
and rate of the development of pHTN, especially the hypothesized transition from 
initially reversible pulmonary arterial vasoconstriction to more fixed and 
irreversible vasculopathy. 
 
Renal/Genitourinary Complications 
Renal complications such as hematuria, proteinuria, pyelonephritis, acute renal 
failure, and chronic renal insufficiency are more common and occur at earlier 
ages in persons with sickle cell disorders compared with individuals without SCD.  
The underlying pathology may be due to the complication of intravascular 
hemolysis or infarction of tissue beyond a vessel blocked by hemoglobin S red 
cells.  Also, once a condition develops, it may recur or progress more rapidly in 
SCD patients.  Nevertheless, renal complications are defined and managed in a 
fashion similar to conditions in individuals without SCD.  However, the initial 
hyperfiltration typical in persons with sickle cell disorders results in a lower serum 
creatinine, so the definition of renal insufficiency is modified accordingly. 
 
Splenic Complications 
Splenic pathology in sickle cell disorders is related to the organ’s unique 
interaction with the sickle erythrocyte and subsequent physiologic dysfunction.  
The relatively hypoxic and acidic splenic environment favors erythrocyte sickling 
and vaso-occlusion.  Intrasplenic vaso-occlusion can be acute, resulting in life-
threatening splenic sequestration (see discussion under Acute Exacerbations of 
Anemia), or chronic, leading to splenic enlargement and hypersplenism with 
peripheral cytopenias.  Vaso-occlusion can lead to an acutely painful infarction of 
the organ but more commonly results in repeated minor subclinical episodes and 
gradual loss of splenic phagocytic and immunologic function in early childhood.  
This functional hyposplenia/asplenia in turn results in increased susceptibility to 
sepsis, particularly from encapsulated bacteria. 
 
Transfusions and Iron Overload 
Patients with SCD receive transfusions for multiple acute and chronic 
complications during their lifetimes, predisposing them to iron overload and 
alloimmunization, even when they are not on chronic transfusion regimens.  
While blood tests such as ferritin and transferrin saturation are helpful in 
identifying patients with risk for iron-mediated tissue damage, they are unreliable 
indicators of the degree of tissue hemosiderosis.  Liver iron analysis is the most 
reliable assessment of iron load, but requires a liver biopsy.  Other assessments 
of liver iron, such as SQUID and MRI T2*, are also reliable and less invasive, but 
not yet widely accessible.  For these reasons, as well as the lack of a carefully 
performed prevalence study, the degree to which iron overload shortens average 
life expectancy for patients with SCD is unclear. 
Alloimmunization, including the production of multiple alloantibodies, is common 
after transfusion in SCD.  Since most SCD patients in the US are African-
American, while most blood donors are Caucasian, efforts to prevent 
alloimmunization are widely recommended, most often through the provision of 
C-, E-, K- red cells to SCD patients negative for these antigens.  Moreover, there 
is a relatively high frequency of delayed hemolytic transfusion reactions in SCD.  
It is important to recognize the unique features such reactions can have in SCD, 
especially the associated vaso-occlusive symptoms and the phenomenon of 
hyperhemolysis, discussed above.  Autoantibodies and reticulocytopenia may 
also be found in this setting.  Therefore, the clinician must be aware that further 
transfusion, even of antigen-matched and crossmatch-compatible blood, may 
result in further exacerbation of anemia and lead to a fatal outcome. 
Summary 
Provision of clinical care and performance of clinical research in SCD have been 
hampered not only by the relatively low prevalence of the disease (<100,000 
persons in the US) but also by the lack of clear definitions and diagnostic criteria 
for the myriad complications of SCD and the burgeoning but still inadequate 
understanding of SCD pathophysiology.  This report therefore proposes 
definitions for the most frequently observed complications of SCD, so that future 
research studies can be used to validate study results and efficacy of treatment 
can be measured.  We believe that these definitions will facilitate future 
genotype-phenotype studies that promise to increase understanding of the 
pathophysiology of SCD complications.  It is the hope of those who supported 
and contributed to this project that this manuscript will be viewed as a dynamic 
document.  A high priority should be given to reevaluation and revision of the 
phenotype definitions at periodic intervals to ensure the most current and 
standardized definitions are available, as better etiologic understandings emerge 
and new diagnostic and treatment options are developed. 
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